2021-10-27 16:00Revenue and Profit - The company's revenue for Q3 2021 reached ¥1,517,745,220.24, representing a 71.83% increase year-over-year[4] - Net profit attributable to shareholders was ¥123,347,581.91, a decrease of 3.29% compared to the same period last year[4] - The net profit excluding non-recurring gains and losses was ¥123,277,703.12, showing a 21.40% increase year-over-year[4] - Revenue for the period reached CNY 4,631,282,401.56, an increase of 30.74% compared to CNY 3,542,478,922.83 in the same period last year, driven by growth in formulation business and heparin sodium sales[11] - Net profit for the period was CNY 457,062,547.37, down 35.30% from CNY 706,425,192.83 in the previous year[11] - The total profit for the period was CNY 553,666,240.92, a decrease of 34.69% compared to CNY 847,806,788.63 in the previous year[11] - Net profit attributable to the parent company was ¥461,505,654.17, down 34.8% from ¥708,597,054.96 in the previous period[31] - The company reported a total comprehensive income attributable to the parent company of ¥464,586,111.21, down from ¥590,339,643.68 in the previous period[33] Cash Flow - Cash flow from operating activities for the year-to-date period was ¥122,722,548.80, reflecting a significant increase of 194.51%[4] - Cash flow from operating activities improved to CNY 122,722,548.80, a 194.51% increase compared to a negative cash flow of CNY -129,851,048.90 last year[11] - Cash flow from investing activities was CNY 1,037,327,922.77, a 167.45% increase from CNY -1,537,910,388.39, mainly due to cash recovered from investments[11] - The net cash flow from operating activities was $122.72 million, a significant improvement from a negative cash flow of $129.85 million in the previous period[37] - The net cash flow from investment activities was $1.04 billion, recovering from a negative cash flow of $1.54 billion in the previous period[37] - Cash inflow from the recovery of investments was $2.43 billion, a significant increase from $163.81 million in the previous period[37] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥19,265,415,690.14, a 1.26% increase from the end of the previous year[4] - The company's cash and cash equivalents increased by 38.41% to ¥3,754,392,520.03 compared to the previous year-end[7] - Inventory levels rose by 31.27% to ¥4,158,961,510.52, attributed to increased stock in line with sales growth trends[7] - Total liabilities increased, with accounts payable rising by 51.15% to CNY 361,571,598.26, attributed to higher raw material purchases[11] - Contract liabilities surged by 80.73% to CNY 479,013,672.13, mainly due to increased prepayments for CDMO services[11] - The total liabilities of the company were RMB 7,443,374,575.00, compared to RMB 7,336,904,566.95 in the previous period[25] - The company's total equity was RMB 11,822,041,115.14, reflecting a slight increase from RMB 11,688,990,087.16[25] Research and Development - Development expenditures surged by 92.03% to ¥28,952,599.77, primarily due to R&D projects at subsidiaries[7] - R&D expenses increased by 56.96% to CNY 108,939,733.97, reflecting higher direct investment in research and development[11] - Research and development expenses rose to ¥108,939,733.97, up 56.9% from ¥69,407,687.52 in the previous period[28] Investment Income - The company reported a significant decrease in investment income, down 91.02% to CNY 26,785,894.69, due to lower returns from long-term equity investments[11] - The company experienced a decrease in investment income, reporting ¥26,785,894.69 compared to ¥298,214,815.65 in the previous period[28] Earnings Per Share - Basic and diluted earnings per share decreased to ¥0.3145 from ¥0.5467 in the previous period[34]